Ling Li

US Patent:

20220226342, Jul 21, 2022

Filed:

Jun 29, 2020

Appl. No.:

17/623060

Inventors:

- Baltimore MD, US
Ling Li - Baltimore MD, US

International Classification:

A61K 31/55
A61P 35/00

Abstract:

Described herein are methods for treating liver tumors and cancer in a subject comprising the steps of administering a suppressor of protein translation to a subject in need thereof. Examples of liver cancer include hepatocellular carcinoma (HCC), cholangiocarcinoma, or a combination thereof. Examples of a suppressor of protein translation includes omacetaxine mepusuccinate, and the methods include combinations with other chemotherapeutic agents.

US Patent:

20230074885, Mar 9, 2023

Filed:

Feb 5, 2021

Appl. No.:

17/797053

Inventors:

- Baltimore MD, US
Hai-Quan Mao - Baltimore MD, US
Ling Li - Baltimore MD, US
Yang Zhou - Baltimore MD, US
Zhiyu He - Baltimore MD, US
Kuntao Chen - Philadelphia PA, US

International Classification:

A61K 47/64
A61K 9/51
A61K 47/54
A61K 45/06
A61P 35/00

Abstract:

The presently disclosed subject matter provides nanoparticles comprising bortezomib encapsulated in a non-water-soluble polymer matrix in a form of a bortezomib-tannic acid complex; methods for preparing the nanoparticle; and use of the nanoparticles for treating liver cancer.

US Patent:

20210333265, Oct 28, 2021

Filed:

Feb 1, 2018

Appl. No.:

16/479652

Inventors:

- Baltimore MD, US
Ling Li - Baltimore MD, US

International Classification:

G01N 33/50
G01N 33/574

Abstract:

The present invention includes methods for identifying chemotherapy treatments specifically suited for each cancer patient using mini-cancers to develop personalized cancer drug regimes.

US Patent:

20200345867, Nov 5, 2020

Filed:

Apr 30, 2020

Appl. No.:

16/864130

Inventors:

- Baltimore MD, US
Vivek Kumbhari - Baltimore MD, US
Ling Li - Baltimore MD, US

International Classification:

A61K 48/00
C12N 15/63
A61P 1/18
A61P 1/16

Abstract:

Intrabiliary hydrodynamic injection of nucleic acid for in vivo gene therapy for treatment of liver or pancreas disease and other disorders.

US Patent:

20200197535, Jun 25, 2020

Filed:

Nov 11, 2019

Appl. No.:

16/679445

Inventors:

- BALTIMORE MD, US
LING LI - BALTIMORE MD, US
STEPHEN J. GOULD - BALTIMORE MD, US

Assignee:

THE JOHNS HOPKINS UNIVERSITY - BALTIMORE MD

International Classification:

A61K 48/00
C12P 1/00
A61K 31/7105
A61K 47/69
G01N 33/574
A61P 25/00
A61K 35/33
A61K 35/13
C12N 15/113
A61K 33/243
C12P 21/00
A61K 9/107
A61K 31/685
A61K 31/704
A61K 33/24
A61K 45/06
C12P 19/34

Abstract:

The present invention relates to the field of extracellular vesicles. More specifically, the present invention provides methods and compositions for using extracellular vesicles as a vector for nucleic acid treatment in vivo of various diseases. In a specific embodiment, the present invention provides an extracellular vesicle isolated from a cell comprising one or more microRNAs (miRNAs) that have been loaded ex vivo into the vesicle so that the miRNAs are present in a higher concentration than when measured in the same extracellular vesicle isolated directly from the cell. In another embodiment, the present invention provides a method for treating cholangiocarcinoma in a subject comprising the step of administering to the subject a plurality of exosomes comprising miR-

US Patent:

20200018743, Jan 16, 2020

Filed:

Sep 26, 2019

Appl. No.:

16/583738

Inventors:

- Baltimore MD, US
Ling Li - Baltimore MD, US

International Classification:

G01N 33/50
G16H 50/30
G16H 50/50
G16H 50/20
G16H 20/10
G16B 40/10

Abstract:

The present invention includes methods for identifying chemotherapy treatments specifically suited for each cancer patient using mini-cancers to develop personalized cancer drug regimes.

US Patent:

20180028687, Feb 1, 2018

Filed:

Jan 29, 2016

Appl. No.:

15/545937

Inventors:

- BALTIMORE MD, US
LING LI - BALTIMORE MD, US
STEPHEN J. GOULD - BALTIMORE MD, US

Assignee:

THE JOHNS HOPKINS UNIVERSITY - BALTIMORE MD

International Classification:

A61K 48/00
A61K 31/704
A61K 33/24
G01N 33/574
A61K 9/107
C12P 19/34
C12P 21/00
A61K 45/06
A61K 31/685

Abstract:

The present invention relates to the field of extracellular vesicles. More specifically, the present invention provides methods and compositions for using extracellular vesicles as a vector for nucleic acid treatment in vivo of various diseases. In a specific embodiment, the present invention provides an extracellular vesicle isolated from a cell comprising one or more microRNAs (miRNAs) that have been loaded ex vivo into the vesicle so that the miRNAs are present in a higher concentration than when measured in the same extracellular vesicle isolated directly from the cell. In another embodiment, the present invention provides a method for treating cholangiocarcinoma in a subject comprising the step of administering to the subject a plurality of exosomes comprising miR-195.

US Patent:

20100319074, Dec 16, 2010

Filed:

Nov 6, 2008

Appl. No.:

12/741645

Inventors:

Patrick Y. Lu - Rockville MD, US
Ling Li - Port St. Lucie FL, US
Vera Simonenko - Germantown MD, US

Assignee:

SIR NAOMICS, INC. - Gaithersburg MD

International Classification:

A61K 31/713
C07H 21/04
A61P 17/02
A61K 49/00

US Classification:

800 3, 536 245, 514 44 A

Abstract:

The present invention provides small interfering RNA (siRNA) molecules, compositions containing them, and methods of using them for improvement of skin scarless wound healing and other skin conditions, such as psoriasis and lupus-caused cutaneous lesions. The invention includes siRNA molecules and compositions containing them that inhibit the expression of one or more genes that promote pathological or undesired processes in wound healing and methods of using them.